 |
50 Diseases |  |
65 Trials |
|
65 Trials |  |
4287 News |  |
| «12...38394041424344454647484950» |
- CDX-3379 / Celldex
Enrollment open: Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 (clinicaltrials.gov) - Jun 27, 2015
P1, N=10, Recruiting, Sponsor: Kolltan Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (clinicaltrials.gov) - Jun 23, 2015
P2, N=46, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date: Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases (clinicaltrials.gov) - Jun 11, 2015
P2, N=20, Not yet recruiting, Sponsor: Sunnybrook Health Sciences Centre
Active, not recruiting --> Completed Trial primary completion date: Dec 2020 --> Oct 2022
- Xalkori (crizotinib) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations (clinicaltrials.gov) - Jun 11, 2015
P1, N=183, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2020 --> Oct 2022 Trial primary completion date: Feb 2016 --> Feb 2017
- Zelboraf (vemurafenib) / Roche
Enrollment open: Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies (clinicaltrials.gov) - Jun 11, 2015
P1, N=15, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2016 --> Feb 2017 Not yet recruiting --> Recruiting
- ||| Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf (clinicaltrials.gov) - Jun 7, 2015
P2, N=100, Active, not recruiting, Sponsor: Cancer Centre of Monoclonal Therapy, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Biomarker, Enrollment open, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jun 1, 2015
P2, N=610, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> Mar 2019
- Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E (clinicaltrials.gov) - Jun 1, 2015
P2, N=31, Active, not recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> Mar 2019 Completed --> Active, not recruiting
- CDX-3379 / Celldex
New P1 trial: Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 (clinicaltrials.gov) - May 28, 2015
P1, N=10, Not yet recruiting, Sponsor: Kolltan Pharmaceuticals, Inc.
- | Zelboraf (vemurafenib) / Roche
New P1 trial: Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies (clinicaltrials.gov) - May 12, 2015
P1, N=15, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma (clinicaltrials.gov) - May 12, 2015
P4, N=60, Active, not recruiting, Sponsor: Hoffmann-La Roche
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- Zelboraf (vemurafenib) / Roche
Trial completion, Trial primary completion date, Metastases: Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E (clinicaltrials.gov) - May 6, 2015
P2, N=31, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Apr 2015
- |||| Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Pfizer
Trial primary completion date, Monotherapy, Metastases: COLUMBUS: Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (clinicaltrials.gov) - Apr 30, 2015
P3, N=900, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Apr 2015 Trial primary completion date: Jun 2017 --> Mar 2018
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (clinicaltrials.gov) - Apr 30, 2015
P1/2, N=20, Recruiting, Sponsor: University of Iowa
Trial primary completion date: Jun 2017 --> Mar 2018 Trial primary completion date: Jun 2014 --> Jun 2015
- Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - Apr 30, 2015
P1, N=114, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Dec 2016 --> Dec 2017
- ||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New P3 trial, Metastases: Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma (clinicaltrials.gov) - Apr 30, 2015
P3, N=20, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- ||| Biomarker, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Apr 14, 2015
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2016 --> Dec 2017 Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2019 --> Nov 2020
- ||| SAR260301 / Sanofi
Trial completion, Combination therapy, Monotherapy, Metastases: A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer (clinicaltrials.gov) - Apr 10, 2015
P1, N=75, Completed, Sponsor: Sanofi
Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2019 --> Nov 2020 Recruiting --> Completed
- Vectibix (panitumumab) / Amgen, Zelboraf (vemurafenib) / Roche
Trial completion: Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 19, 2015
P=N/A, N=16, Completed, Sponsor: Memorial Sloan Kettering Cancer Center.
Recruiting --> Completed Active, not recruiting --> Completed
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor (clinicaltrials.gov) - Mar 17, 2015
P1/2, N=71, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 12, 2015
P1, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2016 --> Feb 2017
- ||| Biomarker, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Mar 10, 2015
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2016 --> Feb 2017 Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> May 2019
- Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations (clinicaltrials.gov) - Feb 24, 2015
P1, N=27, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> May 2019 Trial primary completion date: Feb 2017 --> May 2016
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial initiation date, Trial primary completion date, Metastases: Radiation Use During Vemurafenib Treatment (clinicaltrials.gov) - Feb 24, 2015
P1, N=36, Not yet recruiting, Sponsor: University of Utah
Trial primary completion date: Feb 2017 --> May 2016 Initiation date: Jan 2014 --> Feb 2016 | Trial primary completion date: Nov 2016 --> Feb 2016
- ||| Zelboraf (vemurafenib) / Roche
Trial initiation date: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol (clinicaltrials.gov) - Feb 24, 2015
P4, N=450, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jan 2014 --> Feb 2016 | Trial primary completion date: Nov 2016 --> Feb 2016 Initiation date: Sep 2013 --> Feb 2013
- Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations (clinicaltrials.gov) - Feb 20, 2015
P1, N=27, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Sep 2013 --> Feb 2013 Trial primary completion date: May 2016 --> Feb 2017
- ||| Zelboraf (vemurafenib) / Roche
Trial initiation date: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol (clinicaltrials.gov) - Feb 20, 2015
P4, N=450, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2016 --> Feb 2017 Initiation date: Feb 2013 --> Sep 2013
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zelboraf (vemurafenib) / Roche
Enrollment closed, Trial primary completion date, IO biomarker: Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma (clinicaltrials.gov) - Feb 12, 2015
P2, N=49, Active, not recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Feb 2013 --> Sep 2013 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015
- Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Feb 6, 2015
P1, N=46, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015 Trial primary completion date: Jan 2015 --> Apr 2015
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, IO biomarker, Metastases: The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma (clinicaltrials.gov) - Feb 6, 2015
P2, N=15, Recruiting, Sponsor: Georgetown University
Trial primary completion date: Jan 2015 --> Apr 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- | Zelboraf (vemurafenib) / Roche
Enrollment change: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma (clinicaltrials.gov) - Feb 6, 2015
P2, N=30, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Dec 2014 --> Dec 2015 N=60 --> 30
- Zelboraf (vemurafenib) / Roche, XL888 / Exelixis, Merck (MSD)
Enrollment change, Trial primary completion date: Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma (clinicaltrials.gov) - Feb 6, 2015
P1, N=21, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=60 --> 30 N=36 --> 21 | Trial primary completion date: Apr 2015 --> Sep 2015
- | Zelboraf (vemurafenib) / Roche
Trial completion, Enrollment change, Trial primary completion date, Metastases: A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies (clinicaltrials.gov) - Feb 6, 2015
P1, N=18, Completed, Sponsor: Hoffmann-La Roche
N=36 --> 21 | Trial primary completion date: Apr 2015 --> Sep 2015 Recruiting --> Completed | N=32 --> 18 | Trial primary completion date: Feb 2015 --> Aug 2014
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change, Trial termination, Trial primary completion date, IO biomarker, Metastases: PROCLIVITY 01: HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (clinicaltrials.gov) - Feb 5, 2015
P4, N=53, Terminated, Sponsor: Prometheus Laboratories
Recruiting --> Completed | N=32 --> 18 | Trial primary completion date: Feb 2015 --> Aug 2014 N=185 --> 53 | Recruiting --> Terminated | Trial primary completion date: Apr 2016 --> Nov 2014; slow accrual led to early closure.
- Zelboraf (vemurafenib) / Roche
New P1/2 trial, Combination therapy, Metastases: Vemurafenib and TIL Therapy for Metastatic Melanoma (clinicaltrials.gov) - Feb 3, 2015
P1/2, N=12, Recruiting, Sponsor: Inge Marie Svane
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial initiation date, Combination therapy: CoBRIM-B: Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases (clinicaltrials.gov) - Jan 29, 2015
P2, N=72, Not yet recruiting, Sponsor: Hussein Tawbi
N=185 --> 53 | Recruiting --> Terminated | Trial primary completion date: Apr 2016 --> Nov 2014; slow accrual led to early closure. Initiation date: Aug 2014 --> Feb 2015
- || Zelboraf (vemurafenib) / Roche
Metastases: A Study of Vemurafenib in Participants With Metastatic Melanoma (clinicaltrials.gov) - Jan 28, 2015
P4, N=3285, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Aug 2014 --> Feb 2015 Trial primary completion date: Jan 2015 --> Jul 2015
- ||| Zelboraf (vemurafenib) / Roche
Trial initiation date: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol (clinicaltrials.gov) - Jan 28, 2015
P4, N=450, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2015 --> Jul 2015 Initiation date: Nov 2014 --> Feb 2013
- || SAR260301 / Sanofi
Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer (clinicaltrials.gov) - Jan 22, 2015
P1, N=75, Recruiting, Sponsor: Sanofi
Initiation date: Nov 2014 --> Feb 2013 Trial primary completion date: Sep 2016 --> Apr 2015
- ||| Zelboraf (vemurafenib) / Roche
Trial initiation date: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol (clinicaltrials.gov) - Jan 13, 2015
P4, N=450, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2016 --> Apr 2015 Initiation date: Feb 2013 --> Nov 2014
- |||| Zelboraf (vemurafenib) / Roche
Enrollment open: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol (clinicaltrials.gov) - Dec 25, 2014
P4, N=450, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Feb 2013 --> Nov 2014 Not yet recruiting --> Recruiting
- ||| Biomarker, Enrollment change, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Dec 24, 2014
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=1680 --> 610
- Young TIL / National Cancer Institute
Trial primary completion date, Metastases: Vemurafenib and White Blood Cell Therapy for Advanced Melanoma (clinicaltrials.gov) - Dec 12, 2014
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=1680 --> 610 Trial primary completion date: May 2016 --> Jun 2015
- ||||| New P2 trial, Heterogeneity, PD(L)-1 Biomarker: DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov) - Dec 11, 2014
P2, N=157, Not yet recruiting, Sponsor: University College, London
- Zelboraf (vemurafenib) / Roche
Metastases: Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes (clinicaltrials.gov) - Dec 8, 2014
P=N/A, N=15, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
- |||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Trial primary completion date, Metastases: COMBI-v: Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (clinicaltrials.gov) - Dec 6, 2014
P3, N=704, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2016 --> Jun 2015 Trial primary completion date: Oct 2014 --> Sep 2018
- ||||| Zelboraf (vemurafenib) / Roche
New P2 trial: AcS (clinicaltrials.gov) - Dec 6, 2014
P2, N=500, Recruiting, Sponsor: UNICANCER
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Biomarker, New P2 trial, PD(L)-1 Biomarker: Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC (clinicaltrials.gov) - Dec 1, 2014
P2, N=110, Not yet recruiting, Sponsor: University Hospital Tuebingen
- ||| Zelboraf (vemurafenib) / Roche
Metastases: A Study of Vemurafenib in Participants With Metastatic Melanoma (clinicaltrials.gov) - Nov 25, 2014
P4, N=3255, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2014 --> Sep 2018 Recruiting --> Active, not recruiting
- Zelboraf (vemurafenib) / Roche
Enrollment open, Enrollment change, Metastases: Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E (clinicaltrials.gov) - Nov 20, 2014
P2, N=50, Recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=31 --> 50